These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30864728)

  • 21. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
    Li Q; Deng Q; Chao HP; Liu X; Lu Y; Lin K; Liu B; Tang GW; Zhang D; Tracz A; Jeter C; Rycaj K; Calhoun-Davis T; Huang J; Rubin MA; Beltran H; Shen J; Chatta G; Puzanov I; Mohler JL; Wang J; Zhao R; Kirk J; Chen X; Tang DG
    Nat Commun; 2018 Sep; 9(1):3600. PubMed ID: 30190514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
    Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
    Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
    Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
    Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PLCε knockdown inhibits prostate cancer cell proliferation via suppression of Notch signalling and nuclear translocation of the androgen receptor.
    Wang Y; Wu X; Ou L; Yang X; Wang X; Tang M; Chen E; Luo C
    Cancer Lett; 2015 Jun; 362(1):61-9. PubMed ID: 25796442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
    Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
    Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
    Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
    J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.
    Han Y; Huang W; Liu J; Liu D; Cui Y; Huang R; Yan J; Lei M
    Theranostics; 2017; 7(7):1914-1927. PubMed ID: 28638477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phospholipase Cε Regulates Prostate Cancer Lipid Metabolism and Proliferation by Targeting AMP-Activated Protein Kinase (AMPK)/Sterol Regulatory Element-Binding Protein 1 (SREBP-1) Signaling Pathway.
    Zheng Y; Jin J; Gao Y; Luo C; Wu X; Liu J
    Med Sci Monit; 2020 Jul; 26():e924328. PubMed ID: 32696762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
    Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
    Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
    Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
    Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
    de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
    Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway.
    Yang Y; Wu XH
    Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1918-1923. PubMed ID: 28485785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.